Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immatics NV (IMTX)

Immatics NV (IMTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 711,068
  • Shares Outstanding, K 121,550
  • Annual Sales, $ 168,630 K
  • Annual Income, $ 16,470 K
  • EBIT $ -64 M
  • EBITDA $ -51 M
  • 60-Month Beta 0.83
  • Price/Sales 4.43
  • Price/Cash Flow 25.13
  • Price/Book 1.32

Options Overview Details

View History
  • Implied Volatility 53.78% ( -14.96%)
  • Historical Volatility 65.56%
  • IV Percentile 18%
  • IV Rank 8.30%
  • IV High 423.93% on 05/08/25
  • IV Low 20.26% on 08/26/24
  • Put/Call Vol Ratio 0.63
  • Today's Volume 13
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 3,406
  • Open Int (30-Day) 3,142

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.34
  • Low Estimate -0.41
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -111.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.63 +26.49%
on 05/19/25
6.38 -8.31%
on 06/17/25
+1.11 (+23.42%)
since 05/16/25
3-Month
3.30 +77.27%
on 04/07/25
6.38 -8.31%
on 06/17/25
+0.74 (+14.48%)
since 03/18/25
52-Week
3.30 +77.27%
on 04/07/25
13.09 -55.31%
on 09/16/24
-6.73 (-53.50%)
since 06/18/24

Most Recent Stories

More News
Immatics: Q1 Earnings Snapshot

Immatics: Q1 Earnings Snapshot

IMTX : 5.85 (-4.72%)
Private Sector Steps Up in Cancer Research as Federal Support Wavers

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As the Trump administration signals potential cuts to the National Institutes of Health (NIH), questions...

ONCY : 0.7400 (+10.76%)
SMMT : 20.16 (+1.56%)
CADL : 4.92 (-0.40%)
IMTX : 5.85 (-4.72%)
EXEL : 40.74 (-1.48%)
ONC.TO : 0.97 (-3.96%)
New Strong Buy Stocks for February 12th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Bank of Hawaii Corporation BOH: This bank holding company for Bank of Hawaii has seen the Zacks Consensus Estimate for its current...

RH : 189.10 (+3.51%)
BHRB : 56.26 (+0.29%)
BOH : 65.22 (+0.83%)
IMTX : 5.85 (-4.72%)
AUB : 30.03 (-0.10%)
Immatics N.V. Reports Promising Clinical Data for TCR Bispecific Molecules and Advances Four Cancer Therapy Candidates

Immatics targets five cancer types with TCR-T therapies; recent data shows promising results for TCER® IMA402 and ACTengine® IMA203.Quiver AI SummaryImmatics N.V. announced a strategic expansion of its...

IMTX : 5.85 (-4.72%)
Immatics: Q3 Earnings Snapshot

Immatics: Q3 Earnings Snapshot

IMTX : 5.85 (-4.72%)
Immatics: Q2 Earnings Snapshot

Immatics: Q2 Earnings Snapshot

IMTX : 5.85 (-4.72%)
Immatics: Q1 Earnings Snapshot

Immatics: Q1 Earnings Snapshot

IMTX : 5.85 (-4.72%)
Immatics: Q3 Earnings Snapshot

Immatics: Q3 Earnings Snapshot

IMTX : 5.85 (-4.72%)
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

/PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

IMTX : 5.85 (-4.72%)
PLX : 1.4000 (+2.19%)
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules

IMTX : 5.85 (-4.72%)
MRNA : 25.40 (-0.59%)

Business Summary

Immatics N.V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors. Immatics N.V., formerly known as ARYA SCIENCES, is based in Tuebingen, Germany.

See More

Key Turning Points

3rd Resistance Point 6.52
2nd Resistance Point 6.38
1st Resistance Point 6.12
Last Price 5.85
1st Support Level 5.72
2nd Support Level 5.58
3rd Support Level 5.31

See More

52-Week High 13.09
Fibonacci 61.8% 9.35
Fibonacci 50% 8.19
Fibonacci 38.2% 7.04
Last Price 5.85
52-Week Low 3.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar